hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced the appointment of Cavendish Capital Markets Limited as Nominated Adviser and Joint Broker and Peel Hunt LLP as Joint Broker with immediate effect.
hVIVO appoints Nominated Adviser and Joint Broker
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Latest Company News
Discover how hVIVO's recruitment division sets the gold standard in clinical trials, delivering efficient, tailored participant sourcing for diverse studies.
hVIVO has showcased its excellence in clinical research by successfully executing a large-scale flu vaccine trial, demonstrating agility and operational expertise under tight deadlines.
hVIVO plc announces the release of its 2024 Annual Report and upcoming AGM, along with notable board changes, including the departure of key directors.
Investing in clinical research with FluCamp means supporting innovative healthcare solutions while ensuring participant welfare through unique trial methodologies.
Discover hVIVO's groundbreaking studies on immunomodulators presented at ESCMID 2025, revealing insights into viral infections and host immune responses.
Asthma affects millions, but with the right management and support from FluCamp, individuals can embrace exercise for better health. Discover more today!
